Madrigal general counsel sells 1,077 shares

The reported sale was automatic under a Rule 10b5-1 plan adopted July 31, 2026, before the November 6, 2026 transaction.

Available on EDGAR 11/06/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/06/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Madrigal Pharmaceuticals, Inc. General Counsel Shannon T. Kelley sold 1,077 shares of common stock on November 6, 2026, at $400 per share. The sale was effected automatically under a Rule 10b5-1 trading plan Kelley adopted on July 31, 2026. After the transaction, Kelley directly held 10,397 shares.

Insider Trade Summary 10b5-1

Net Seller: 1,077 shares

Net Sell 1 txn

Insider Kelley Shannon T

Role General Counsel

Sold 1,077 shs ($431K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,077	$400.00	$431K

Holdings After Transaction: Common Stock — 10,397 shares (Direct)

Footnotes (1)

1. F1. This sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2026.

Key Figures

Shares sold: 1,077 shares Sale price: $400 per share Direct holdings after transaction: 10,397 shares +1 more

4 metrics

Shares sold 1,077 shares Common stock sold on November 6, 2026

Sale price $400 per share Sale on November 6, 2026

Direct holdings after transaction 10,397 shares After the November 6, 2026 sale

Plan adoption date July 31, 2026 Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan

1 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MDGL shares did General Counsel Shannon T. Kelley sell?

General Counsel Shannon T. Kelley sold 1,077 shares of Madrigal Pharmaceuticals, Inc. common stock on November 6, 2026, at $400 per share. The sale was automatic under a Rule 10b5-1 plan adopted July 31, 2026, and Kelley directly held 10,397 shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelley Shannon T

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

1001 CONSHOHOCKEN STATE ROAD SUITE 2-350

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2026		S(1)		1,077	D	$400	10,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2026.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)